Profile: Allergan plc (AGN)
24 Feb 2017
Allergan plc, incorporated on May 16, 2013, is a global pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. The Company is also is focused on developing, manufacturing and commercializing select over-the-counter (OTC) products. The Company’s segments include US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes branded products within the United States, including medical aesthetics, medical dermatology, eye care, neurosciences and urology therapeutic products. The US General Medicine segment includes branded products within the United States, including central nervous system, gastrointestinal, women’s health, anti-infectives and other brands. The International segment includes products sold outside the United States.
The Company markets a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. The Company is also engaged in regenerative medicines business. The Company offers a range of dermal matrix products. The Company’s products include Botox, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin, Estrace, Viibryd, Asacol, Minastrin 24, Aczone, Ozurdex, Carafate and Namenda IR.
Clonshaugh Business And Technolo
DUBLIN D17 E400
Company Web Links
- BRIEF-Allergan says Goldman Sachs Group reported 6.3 pct passive stake in co as of Dec. 31 - SEC filing
- Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
- UPDATE 4-Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 bln
- Allergan adds ice and a slice to M&A cocktail
- CORRECTED-UPDATE 2-Allergan to buy Zeltiq Aesthetics for about $2.48 bln